Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Dealing with absolute and relative contraindications to specific immunotherapy using Hymenoptera venoms

Dealing with absolute and relative contraindications to specific immunotherapy using Hymenoptera... review Allergo J Int (2017) 26:122–128 DOI 10.1007/s40629-017-0024-0 Dealing with absolute and relative contraindications to specific immunotherapy using Hymenoptera venoms Andrea Bauer · Franziska Ruëff Received: 19 February 2017 / Accepted: 17 March 2017 / Published online: 4 May 2017 © Springer Medizin Verlag GmbH 2017 Abstract tion of HV-SIT. Some of these contraindications are, by Background Acute infectious disorders, uncontrolled their very nature, temporary. In other cases, therapy bronchial asthma, severe chronic inflammatory dis- can be initiated once the underlying disease has been orders, severe cardiovascular disorders, autoimmune optimally treated. Relative contraindications to the or immunodeficiency disorders, active or progres- initiation of HV-SIT include autoimmune disorders in sive cancer, acquired immunodeficiency syndrome remission, immune defects and immunosuppressive (AIDS), treatment initiation during pregnancy, as well therapy, well-controlled chronic infectious diseases, as medication with β-blockers and angiotensin-con- category A and B HIV, partially controlled bronchial verting enzyme (ACE) inhibitors, among others, are asthma, limited compliance, age below 5 years, can- considered either absolute or relative contraindica- cer in remission, comedication with ACE inhibitors tions to specific immunotherapy using Hymenoptera and β-blockers, as well as treatment (continuation) venom (HV-SIT). Some of the contraindications listed during pregnancy. In the case of relative http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Allergo Journal International Springer Journals

Dealing with absolute and relative contraindications to specific immunotherapy using Hymenoptera venoms

Download PDF
7 pages

Loading next page...
 
/lp/springer-journals/dealing-with-absolute-and-relative-contraindications-to-specific-FJOd0GANgM
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer Medizin Verlag GmbH
Subject
Medicine & Public Health; Allergology; Dermatology; Environmental Health; Immunology
eISSN
2197-0378
DOI
10.1007/s40629-017-0024-0
Publisher site
See Article on Publisher Site

Abstract

review Allergo J Int (2017) 26:122–128 DOI 10.1007/s40629-017-0024-0 Dealing with absolute and relative contraindications to specific immunotherapy using Hymenoptera venoms Andrea Bauer · Franziska Ruëff Received: 19 February 2017 / Accepted: 17 March 2017 / Published online: 4 May 2017 © Springer Medizin Verlag GmbH 2017 Abstract tion of HV-SIT. Some of these contraindications are, by Background Acute infectious disorders, uncontrolled their very nature, temporary. In other cases, therapy bronchial asthma, severe chronic inflammatory dis- can be initiated once the underlying disease has been orders, severe cardiovascular disorders, autoimmune optimally treated. Relative contraindications to the or immunodeficiency disorders, active or progres- initiation of HV-SIT include autoimmune disorders in sive cancer, acquired immunodeficiency syndrome remission, immune defects and immunosuppressive (AIDS), treatment initiation during pregnancy, as well therapy, well-controlled chronic infectious diseases, as medication with β-blockers and angiotensin-con- category A and B HIV, partially controlled bronchial verting enzyme (ACE) inhibitors, among others, are asthma, limited compliance, age below 5 years, can- considered either absolute or relative contraindica- cer in remission, comedication with ACE inhibitors tions to specific immunotherapy using Hymenoptera and β-blockers, as well as treatment (continuation) venom (HV-SIT). Some of the contraindications listed during pregnancy. In the case of relative

Journal

Allergo Journal International – Springer Journals

Published: May 4, 2017

References

  • Diagnose und Therapie der Bienen und Wespengiftallergie
    Przybilla, B; Ruëff, F; Walker, A; Räwer, HC; Aberer, W; Bauer, CP
  • EAACI Interest Group on Insect Venom Hypersensitivity. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice
    Bonifazi, F; Jutel, M; Biló, BM; Birnbaum, J; Muller, U
  • Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. European Academy of Allergology and Clinical Immunology
    Mosbech, H; Müller, U
  • Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase – a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity
    Ruëff, F; Przybilla, B; Biló, MB; Müller, U; Scheipl, F; Aberer, W
  • Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD)
    Pfaar, O; Bachert, C; Bufe, A; Buhl, R; Ebner, C; Eng, P
  • Clinical contraindications to allergen immunotherapy: an EAACI position paper
    Pitsios, C; Demoly, P; Bilò, MB; Gerth van Wijk, R; Pfaar, O; Sturm, GJ
  • AIDS, HIV-positive patients, and allergies
    Marshall, GD
  • Allergen immunotherapy in a patient with human immunodeficiency virus: effect on T‑cell activation and viral replication
    Randhawa, IS; Junaid, I; Klaustermeyer, WB
  • Specific immunotherapy in a pollen-allergic patient with human immunodeficiency virus infection
    Steiner, UC; Furrer, H; Helbling, A
  • Subcutaneous allergen immunotherapy in 3 patients with HIV
    Fodeman, J; Jariwala, S; Hudes, G; Jerschow, E; Rosenstreich, D
  • Allergen immunotherapy: a practice parameter third update
    Cox, L; Nelson, H; Lockey, R; Calabria, C; Chacko, T; Finegold, I; Nelson, M; Weber, R; Bernstein, DI
  • Immunotherapy for allergic rhinitis
    Walker, SM; Durham, SR; Till, SJ; Roberts, G; Corrigan, CJ; Leech, SC
  • Manifestation of rheumatoid arthritis during subcutaneous allergen-specific immunotherapy with bee venom
    Ghoreschi, K; Fischer, J; Biedermann, T
  • Safety of allergenic immunotherapy in systemic lupus erythematodes
    Fiorillo, A; Fonacier, I; Diola, C
  • Subcutaneous sarcoidosis localised to sites of previous desensitizing injections
    Marcoval, J; Moreno, A; Mañá, J
  • Cardiovascular disease and anaphylaxis
    Mueller, UR
  • Hymenopterengiftanaphylaxie und Herz-Kreislauf-Erkrankungen
    Müller, UR
  • Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase
    Ruëff, F; Przybilla, B; Biló, MB; Müller, U; Scheipl, F; Aberer, W
  • Role of mast cells in atherosclerosis: a classical inflammatory disease
    Spinas, E; Kritas, SK; Saggini, A; Mobili, A; Caraffa, A; Antinolfi, P
  • Antihypertensive medication use is associated with increased organ system involvement and hospitalization in emergency department patients with anaphylaxis
    Lee, S; Hess, EP; Nestler, DM; Bellamkonda Athmaram, VR; Bellolio, MF; Decker, WW
  • Ramipril and metoprolol intake aggravate human and murine anaphylaxis: evidence for direct mast cell priming
    Nassiri, M; Babina, M; Dölle, S; Edenharter, G; Ruëff, F; Worm, M
  • beta Blockade after myocardial infarction: systematic review and meta regression analysis
    Freemantle, N; Cleland, J; Young, P; Mason, J; Harrison, J
  • beta-Blockers in heart failure: clinical applications
    Farrell, MH; Foody, JM; Krumholz, HM
  • beta-Blocker therapy in heart failure: scientific review
    Foody, JM; Farrell, MH; Krumholz, HM
  • Hypersensitivity to histamine and systemic anaphylaxis in mice with pharmacologic beta adrenergic blockade: protection by nucleotides
    Matsumura, Y; Tan, EM; Vaughan, JH
  • Anaphylactoid and anaphylactic reactions. Hazards of beta-blockers
    Lang, DM
  • Antagonism by beta-adrenoceptor blocking agents of the antianaphylactic effect of isoprenaline
    Assem, ES; Schild, HO
  • Potentiated anaphylaxis in patients with drug-induced beta-adrenergic blockade
    Jacobs, RL; Rake, GW; Fournier, DC; Chilton, RJ; Culver, WG; Beckmann, CH
  • Severe anaphylaxis and drug-induced beta-blockade
    Hannaway, PJ; Hopper, GD
  • Insect sting anaphylaxis and beta-adrenergic blockade: a relative contraindication
    Awai, LE; Mekori, YA
  • Beta-blockade in stinging insect anaphylaxis
    Ingall, M; Goldman, G; Page, LB
  • Beta-blocker therapy and the risk of anaphylaxis
    Toogood, JH
  • Do beta-blockers really enhance the risk of anaphylaxis during immunotherapy?
    Lang, DM
  • Bronchial and cardiovascular effects of ocular topical B‑antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol
    Jeunne, CL; Hugues, FC; Dufier, JL; Munera, Y; Bringer, L
  • Use of beta-blockers during immunotherapy for hymenoptera venom allergy
    Müller, UR; Haeberli, G
  • Over- and underestimated parameters in severe Hymenoptera venom-induced anaphylaxis: cardiovascular medication and absence of urticaria/angioedema
    Stoevesandt, J; Hain, J; Kerstan, A; Trautmann, A
  • Risk of systemic reactions in patients taking beta-blocker drugs receiving allergen immunotherapy injections
    Hepner, MJ; Ownby, DR; Anderson, JA; Rowe, MS; Sears-Ewald, D; Brown, EB
  • Immunological and clinical factors associated with adverse systemic reactions during the build-up phase of honeybee venom immunotherapy
    Korošec, P; Žiberna, K; Šilar, M; Dežman, M; Čelesnik Smodiš, N; Rijavec, M
  • Hymenoptera venom immunotherapy while maintaining cardiovascular medication: safe and effective
    Stoevesandt, J; Hosp, C; Kerstan, A; Trautmann, A
  • Safety and tolerability during build-up phase of a rush venom immunotherapy
    Bernkopf, K; Rönsch, H; Spornraft-Ragaller, P; Neumeister, V; Bauer, A
  • Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology
    López-Sendón, J; Swedberg, K; McMurray, J; Tamargo, J; Maggioni, AP; Dargie, H
  • The renin angiotensin system and hymenoptera venom anaphylaxis
    Hermann, K; Ring, J
  • Histamine, tryptase, norepinephrine, angiotensinogen, angiotensin-converting enzyme, angiotensin I and II in plasma of patients with hymenoptera venom anaphylaxis
    Hermann, K; Tschirschnitz, M; Ebner von Eschenbach, C; Ring, J
  • The renin-angiotensin system in patients with repeated anaphylactic reactions during hymenoptera venom hyposensitization and sting challenge
    Hermann, K; Ring, J
  • The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins
    Blais, C; Marceau, F; Rouleau, JL; Adam, A
  • Plasma bradykinin in angio-oedema
    Nussberger, J; Cugno, M; Amstutz, C; Cicardi, M; Pellacani, A; Agostoni, A
  • Angiotensin-converting enzyme inhibitors do not impair the safety of hymenoptera venom immunotherapy build-up phase
    Stoevesandt, J; Hain, J; Stolze, I; Kerstan, A; Trautmann, A
  • Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity
    Ruëff, F; Przybilla, B; Biló, MB; Müller, U; Scheipl, F; Seitz, MJ
  • Predictors of clinical effectiveness of hymenoptera venom immunotherapy
    Ruëff, F; Vos, B; Oude Elberink, J; Bender, A; Chatelain, R; Dugas-Breit, S
  • Malignancy and specific allergen immunotherapy: the results of a case series
    Wöhrl, S; Kinaciyan, T; Jalili, A; Stingl, G; Moritz, KB
  • The value of immunotherapy with venom in children with allergy to insect stings
    Valentine, MD; Schuberth, KC; Kagey-Sobotka, A; Graft, DF; Kwiterovich, KA; Szklo, M
  • An epidemiological survey of hymenoptera venom allergy in the Spanish paediatric population
    Martínez-Cañavate, A; Tabar, AI; Eseverri, JL; Martín, F; Pedemonte-Marco, C
  • Uterine contractions are known side effects of venom immunotherapy
    Helbling, A; Müller, UR; Hausmann, O
  • Anaphylaxis during pregnancy
    Simons, FE; Schatz, M
  • Venom immunotherapy in the Hymenoptera-allergic pregnant patient
    Schwartz, HJ; Golden, DB; Lockey, RF
  • The safety of immunotherapy during pregnancy
    Metzger, WJ; Turner, E; Patterson, R
  • Uterine contractions: an unusual side effect of venom immunotherapy
    Karakurt, F; Kargili, A; Bozkurt, B; Kasapoglu, B; Ikizek, M
  • Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement
    Kowalski, ML; Ansotegui, I; Aberer, W; Al-Ahmad, M; Akdis, M; Ballmer-Weber, BK